Cowen


Top Analyst Cuts Price Target For Intercept Pharmaceuticals Inc (ICPT) By 50%; Here’s Why

Intercept Sank 40% in September following Dear Doctor and FDA warning letters; Ritu Baral weighs in.

Alnylam Pharmaceuticals, Inc. (ALNY) Picks Up a Price Target Boost from Cowen Following Stellar Phase III Top-Line Data in FAP

Analyst praises Alnylam’s patisiran as best-in-class, even more confident in its safety and tolerability profile.

Top Analyst Boosts Price Target for Aldeyra Therapeutics Inc (ALDX); Here’s Why

Ritu Baral sees 35% upside for Aldeyra on back of positive Phase 2a dry eye study.

Cowen Positive on Sarepta Therapeutics Inc (SRPT) Following Successful Early-Stage DMD Trial

Analyst upbeat on boosted dystrophin expression levels in Sarepta’s lead candidate golodirsen.

Cowen Sees High 80% Probability of FDA Approval for Insmed Incorporated’s (INSM) NTM Drug

Insmed’s lead asset ALIS poses compelling prospects for commercial success in the U.S.

Ultragenyx Pharmaceutical Inc (RARE) Tumbles on Ace-ER Failure; Top Analyst Remains Bullish

Cowen Sees Light at the End of the Tunnel for Ultragenyx Following a Failed Phase 3 Study in GNEM

Myokardia Inc (MYOK) Heart Drug Very Likely to Achieve FDA Breakthrough Status: Cowen

It is a nice time to be a Myokardia Inc (NASDAQ:MYOK) investor, particularly on back of the biotech firm’s successful Phase 2a PIONEER …

Genocea Biosciences Inc (GNCA) May Be Crashing, But Here’s Why Cowen Sees A Significantly Undervalued Stock

Genocea Biosciences Inc (NASDAQ:GNCA) shares were plummeting almost 15% yesterday after the biotech firm and are another 5% dive today after a lackluster …